Novel small molecule and TCM approaches to support pig production, minimizing generation of resistance to human antibiotics
Lead Participant:
OXFORD DRUG DESIGN LIMITED
Abstract
The emergence of resistance to antibiotics is a major health concern. To address this concern, this project will
address multiple aspects of antibacterial resistance, bringing together complementary expertise in the UK and
China. Antibiotics are widely used in agriculture, where they have a valid role in protecting farm animals from
disease and increasing food production. However, the use of antibiotics that are also used to treat humans
could lead to increased antimicrobial resistance. One of the aims of this project is to develop a new class of
antibiotics that are specific to a species of bacteria that cause infections in pigs, which would enable reduced
use of human antibiotics in farming. A second aspect of the proposal is to investigate the use of traditional
Chinese medicines (TCMs) in veterinary settings. TCMs are typically complex mixtures with unknown
mechanism of action. We will use sophisticated computational modelling methods, specifically a technique
called chemgenomics, to identify the active components of TCMs, which may enable further classes of
antibiotic to be rationally designed, or to be used synergistically with existing compounds.
address multiple aspects of antibacterial resistance, bringing together complementary expertise in the UK and
China. Antibiotics are widely used in agriculture, where they have a valid role in protecting farm animals from
disease and increasing food production. However, the use of antibiotics that are also used to treat humans
could lead to increased antimicrobial resistance. One of the aims of this project is to develop a new class of
antibiotics that are specific to a species of bacteria that cause infections in pigs, which would enable reduced
use of human antibiotics in farming. A second aspect of the proposal is to investigate the use of traditional
Chinese medicines (TCMs) in veterinary settings. TCMs are typically complex mixtures with unknown
mechanism of action. We will use sophisticated computational modelling methods, specifically a technique
called chemgenomics, to identify the active components of TCMs, which may enable further classes of
antibiotic to be rationally designed, or to be used synergistically with existing compounds.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
OXFORD DRUG DESIGN LIMITED | £805,788 | £ 564,052 |
  | ||
Participant |
||
DENTHERAPY LIMITED | ||
UNIVERSITY OF PORTSMOUTH | ||
UNIVERSITY OF PORTSMOUTH | £166,895 | £ 166,895 |
People |
ORCID iD |
Paul Finn (Project Manager) |